Northrop Grumman Corporation
announced that it has entered into a confidentiality agreement
with TRW Inc. on terms that are acceptable to both companies. As
a result, Northrop Grumman expects to commence its due diligence process
shortly. The company also said that it has extended its pending exchange
offer for all outstanding shares of common and preferred stock of TRW Inc.
from May 3, 2002, to May 17, 2002, at midnight EDT.

Approximately 3,185,000 shares of TRW common stock; 1,365,000 shares of
Cumulative Serial Preference Stock II, $4.40 Convertible Series 1; and 3,400
shares of Cumulative Serial Preference Stock II, $4.50 Convertible Series 3
had been tendered to Northrop Grumman as of 5:00 p.m. EDT on May 3, 2002, of
which approximately 1,000,000 shares of common stock were tendered pursuant to
notices of guaranteed delivery. The tendered shares are subject to validation
by TRW’s transfer agent.

Northrop Grumman Corporation is an $18 billion, global defense company
with its worldwide headquarters in Los Angeles. Northrop Grumman provides
technologically advanced, innovative products, services and solutions in
defense and commerptio electronics, systems integration, information
technology and nuclear and non-nuclear shipbuilding and systems. With nearly
100,000 employees and operations in 44 states and 25 countries, Northrop
Grumman serves U.S. and international military, government and commercial

Northrop Grumman filed a registration statement on Form S-4 (File No.
333-83672) and a tender offer statement on Schedule TO with the SEC on March
4, 2002 with respect to its offer to exchange all outstanding shares of TRW
capital stock for Northrop Grumman stock. These documents contain important
information. TRW shareholders should read these documents and any amendments
or supplements thereto before making any decision regarding the offer to
exchange. Copies of such documents may be obtained without charge at the
SEC’s website at or from D.F. King & Co., Inc. the information
agent for the offer to exchange, at 800-755-7250.